Danshen (Salvia miltiorrhiza) trials recruiting now

1 registration that name danshen as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.

Trial Finder Read from ClinicalTrials.gov Oct 20, 2026 The Danshen (Salvia miltiorrhiza) supplement page

Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.

Filter 1 registration

Status

All 1 registrations

Not yet recruitingNCT06727890

Compound Danshen Dripping Pill for Diabetic Microvascular Angina

  • Phase 4
  • Qilu Hospital of Shandong University
  • About 162 people
  • Starts Jan 1, 2025 (estimated)

In plain words A Phase 4 study of danshen in people 18 and older, run by Qilu Hospital of Shandong University. It plans to enroll about 162 people at 3 sites, none in the US.

Who it lists and where

Who the trial lists, as registered

Lists people 18 and older. Conditions: Diabetic Microvascular Angina.

What it tests, as registered

Danshen Dripping Pill; Placebo

Registered summary

To investigate the efficacy and safety of Compound Danshen Dripping Pill in patients with diabetic microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Compound Danshen Dripping Pill on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.

Where, as registered

No US site; China (3).

ClinicalTrials.gov lists 15 open registrations for this search, including ones where danshen is not a study arm or that are past the 1 we keep. Search them on ClinicalTrials.gov (opens in new tab).

Also on Kymata

Supplement brands we have checkedEvery supplement brand we have reviewed.

Educational only. Not medical advice. Some links earn us a commission: kymatahealth.com/affiliate-disclosure.